Study highlights risks of Ozempic and weight loss drugs for kidney and gastrointestinal health

A new study in Nature Medicine reveals that GLP-1 medications, including Ozempic and Mounjaro, may increase risks of kidney, pancreatic, and gastrointestinal issues, despite their effectiveness in weight loss and appetite control. Researchers analyzed data from over 2 million diabetes patients, noting both benefits and potential severe side effects of these drugs. While they can reduce risks of addiction and neurocognitive disorders, they may also cause nausea, vomiting, and serious complications like pancreatitis. The study emphasizes the need for ongoing monitoring of kidney function and awareness of these risks among users of GLP-1 medications, as some side effects can develop without noticeable symptoms.